EICHOR
● Active Not Recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Seagen, a wholly owned subsidiary of Pfizer
About this study
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle. This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (331)
| Alaska Oncology and Hematology, LLC | Anchorage, Alaska, United States | — |
| Providence Medical Foundation | Fullerton, California, United States | — |
| Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center | Fullerton, California, United States | — |
| Providence St. Jude Medical Center | Fullerton, California, United States | — |
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | — |
| Cancer Blood and Specialty Clinic | Los Alamitos, California, United States | — |
| Regulatory Management Only: TRIO-US Central Administration | Los Angeles, California, United States | — |
| Drug Management Only: UCLA West Medical Pharmacy Attn: Steven L. Wong, Pharma.D. | Los Angeles, California, United States | — |
| Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D. | Los Angeles, California, United States | — |
| UCSF Medical Center - Mission Bay | San Francisco, California, United States | — |
| Sansum Clinic | Santa Barbara, California, United States | — |
| Sansum Clinic | Solvang, California, United States | — |
+ 319 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06012435